Answers are grounded in this paper and cite their sources.
Background Obesity and periodontitis are among the most common chronic disorders affecting the world population, while Prolactin (PRL) is a neuroendocrine hormone that within the physiological range stimulates bone formation but can induce bone resorption and inhibit bone formation at elevated levels. This study aimed to investigate prolactin (PRL) levels in gingival crevicular fluid (GCF) in obese (O) patients with and without stage II and III periodontitis (P). Further, to evaluate the effect of non-surgical periodontal therapy (NSPT) on these levels after 3 months in cases compared to controls. Materials and methods The study included 26 obese patients allocated into two groups: Group 1 ( n = 13) with healthy periodontium (O), and Group 2 ( n = 13) with Stage II and III periodontitis (O + P). Periodontitis patients in Group 2 received NSPT. GCF prolactin was measured using enzyme-linked immunosorbent assay (ELISA) before and after 3 months of NSPT. A linear mixed model was used to compare GCF prolactin levels among the study conditions. Results Baseline GCF prolactin concentrations were significantly higher in obese patients with periodontitis than in obese participants with a healthy periodontium (6.35 ± 2.36 vs. 4.62 ± 1.32 ng/mL; p₁ = 0.037). Following NSPT, GCF prolactin levels in the periodontitis group decreased significantly to 4.21 ± 1.04 ng/mL (p₃ = 0.007). No significant difference was observed between the control group and the periodontitis group after NSPT (p₂ = 1.00). Overall, the linear mixed model demonstrated a significant difference among the study conditions (F = 5.99, p = 0.006). Conclusion NSPT significantly decreased GCF prolactin levels in obese patients with Stage II and III periodontitis. This suggests that elevated PRL may represent a promising biomarker candidate associated with active periodontal disease, and its reduction indicates a dynamic role for local prolactin during periodontal healing and inflammation resolution in obese individuals, warranting further investigation into its functional implications and biomarker potential. Trial registration This trial was retrospectively registered at ClinicalTrials.gov (ID: NCT07571850, Date of registration:18/4/2026; https://clinicaltrials.gov/study/NCT07571850 ).
No takes yet. Share an insight, caveat, or question.
Marie et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: